Arthur N. Kales

Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.

Jean L. Grem, Emmet Jordan, Matthew Robson et al. · Journal of Clinical Oncology · 1993 · 68 citations

Oncology, Gastrointestinal Oncology, Medicine +15

A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression

Roy Beveridge, John A. Miller, Arthur N. Kales et al. · Cancer Investigation · 1998 · 64 citations

Simultaneous presentation of acute myelomonocytic leukemia and multiple myeloma

Brian Cleary, Richard A. Binder, Arthur N. Kales et al. · Cancer · 1978 · 42 citations · Full text

Hematological Malignancy, Simultaneous Presentation, Possible Mechanisms +13

Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy

Roy Beveridge, John A. Miller, Arthur N. Kales et al. · Supportive Care in Cancer · 1997 · 33 citations

Hematological Malignancy, Bacteria-derived Rhug-csf, Medicine +10

Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.

John A. Miller, T. Butler, Roy Beveridge et al. · PubMed · 1993 · 22 citations